NCT04987489: An ongoing trial by Forma Therapeutics, Inc.
This trial is ongoing. It must report results 8 months, 3 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04987489 |
|---|---|
| Title | A Phase 2 Open-Label Study to Evaluate Safety and Clinical Activity of Etavopivat in Patients With Thalassemia or Sickle Cell Disease |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 28, 2022 |
| Completion date | Sept. 3, 2025 |
| Required reporting date | Sept. 3, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |